These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3121365)

  • 1. The effects of kainic acid and 6-hydroxydopamine lesions, metal ions and GTP on in vitro binding of the D-2 dopamine agonist, [3H]N-0437, to striatal membranes.
    Van der Weide J; De Vries JB; Tepper PG; Horn AS
    Eur J Pharmacol; 1987 Nov; 143(1):101-7. PubMed ID: 3121365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-0437: a selective D-2 dopamine receptor agonist in in vitro and in vivo models.
    Van der Weide J; De Vries JB; Tepper PG; Krause DN; Dubocovich ML; Horn AS
    Eur J Pharmacol; 1988 Mar; 147(2):249-58. PubMed ID: 3130270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro binding of the very potent and selective D-2 dopamine agonist, [3H]N-0437 to calf caudate membranes.
    Van der Weide J; De Vries JB; Tepper PG; Horn AS
    Eur J Pharmacol; 1987 Feb; 134(2):211-9. PubMed ID: 3569410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioreceptor binding reveals the potencies of N,N-disubstituted 2-aminotetralins as D2 dopamine agonists.
    Beart PM; Cook CJ; Cincotta M; de Vries DJ; Tepper P; Dijkstra D; Horn AS
    Naunyn Schmiedebergs Arch Pharmacol; 1987 Nov; 336(5):487-93. PubMed ID: 2963964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of striatal dopamine release by the selective D-2 dopamine receptor agonist N-0437 is blocked by quinine.
    Cass WA; Zahniser NR
    Synapse; 1990; 5(4):336-7. PubMed ID: 2141733
    [No Abstract]   [Full Text] [Related]  

  • 6. Reversible decrease in dopaminergic 3H-agonist binding after 6-hydroxydopamine and irreversible decrease after kainic acid.
    Schweitzer BI; Bacopoulos NG
    Life Sci; 1983 Jan; 32(5):531-40. PubMed ID: 6296593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further in vitro and in vivo studies with the putative presynaptic dopamine agonist N,N-dipropyl-7-hydroxy-2-aminotetralin.
    Mulder TB; de Vries JB; Dijkstra D; Wiechers JW; Grol CJ; Horn AS
    Naunyn Schmiedebergs Arch Pharmacol; 1987 Nov; 336(5):494-501. PubMed ID: 2830544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of [3H]apomorphine to striatal membranes prepared from rat brain after 6-hydroxydopamine and kainic acid lesions.
    Fujita N; Saito K; Iwatsubo K; Hirata A; Noguchi Y; Yoshida H
    Brain Res; 1980 May; 190(2):593-6. PubMed ID: 7370810
    [No Abstract]   [Full Text] [Related]  

  • 9. The enantiomers of the dopamine agonist N-0437: in vivo and in vitro effects on the release of striatal dopamine.
    Timmerman W; Dubocovich ML; Westerink BH; De Vries JB; Tepper PG; Horn AS
    Eur J Pharmacol; 1989 Jul; 166(1):1-11. PubMed ID: 2572424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding characteristics of the dopamine uptake inhibitor [3H]nomifensine to striatal membranes.
    Dubocovich ML; Zahniser NR
    Biochem Pharmacol; 1985 Apr; 34(8):1137-44. PubMed ID: 3158318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microdialysis and striatal dopamine release: stereoselective actions of the enantiomers of N-0437.
    Timmerman W; Westerink BH; De Vries JB; Tepper PG; Horn AS
    Eur J Pharmacol; 1989 Mar; 162(1):143-50. PubMed ID: 2566492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo binding of N-n-propylnorapomorphine in the rat striatum: quantification after lesions produced by kainate, 6-hydroxydopamine and decortication.
    Van der Werf JF; Sebens JB; Korf J
    Eur J Pharmacol; 1984 Jul; 102(2):251-9. PubMed ID: 6434329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of rat striatal dopamine D-1 receptors solubilized by digitonin with a precipitation method.
    Zhang X; Segawa T
    Eur J Pharmacol; 1989 Aug; 166(3):401-10. PubMed ID: 2680521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sodium dependent [3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinsons disease.
    Schoemaker H; Pimoule C; Arbilla S; Scatton B; Javoy-Agid F; Langer SZ
    Naunyn Schmiedebergs Arch Pharmacol; 1985 May; 329(3):227-35. PubMed ID: 3927176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Properties of dopamine agonist and antagonist binding sites in mammalian retina.
    Makman MH; Dvorkin B; Horowitz SG; Thal LJ
    Brain Res; 1980 Aug; 194(2):403-18. PubMed ID: 6770965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclohexyladenosine binding in rat striatum.
    Lloyd HG; Stone TW
    Brain Res; 1985 May; 334(2):385-8. PubMed ID: 2986787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic and pharmacological profiles of the in vitro binding of the potent dopamine agonist [3H]N,N-dipropyl-5,6-dihydroxy-2-aminotetralin to rat striatal membranes.
    Mulder TB; Grol CJ; Dijkstra D; Horn AS
    Eur J Pharmacol; 1985 May; 112(1):73-9. PubMed ID: 4018139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kainic acid lesions of striatum and decortication reduce specific [3H]sulpiride binding in rats, so D-2 receptors exist post-synaptically on corticostriate afferents and striatal neurons.
    Theodorou A; Reavill C; Jenner P; Marsden CD
    J Pharm Pharmacol; 1981 Jul; 33(7):439-44. PubMed ID: 6115030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of GTP and sodium on rat striatal dopamine receptors labeled with lisuride.
    Uzumaki H; Govoni S; Memo M; Carruba MO; Trabucchi M; Spano PF
    Brain Res; 1982 Sep; 248(1):185-7. PubMed ID: 7127137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of heavy metal cations, sulfhydryl reagents and other chemical agents on striatal D2 dopamine receptors.
    Scheuhammer AM; Cherian MG
    Biochem Pharmacol; 1985 Oct; 34(19):3405-13. PubMed ID: 3931643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.